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Background: Acute hypokalaemic paralysis is characterised by acute flaccid muscle weakness and has a complex
aetiological spectrum. Herein we report, for the first time, a case of unilateral adrenal hyperplasia accompanied by
hypokalaemic periodic paralysis type I resulting from a novel dominant mutation in CACNA1S. We present the
clinical features and prognosis after adrenalectomy in this case.
Case presentation: A 43-year-old Han Chinese male presented with severe hypokalaemic paralysis that remitted
after taking oral potassium. The patient had suffered from periodic attacks of hypokalaemic paralysis for more than
20 years. A computed tomography (CT) scan of the abdomen showed a nodular mass on the left adrenal gland,
although laboratory examination revealed the patient had not developed primary aldosteronism. The patient
underwent a left adrenalectomy 4 days after admission, and the pathological examination further confirmed a 1.1 cm
benign nodule at the periphery of the adrenal gland. Three months after the adrenalectomy, a paralytic attack recurred
and the patient asked for assistance from the Department of Medical Genetics. His family history showed that two
uncles, one brother, and a nephew also had a history of periodic paralysis, although their symptoms were milder. The
patient’s CACNA1S and SCN4A genes were sequenced, and a novel missense mutation, c.1582C > T (p.Arg528Cys), in
CACNA1S was detected. Detection of the mutation in five adult male family members, including three with periodic
paralysis and two with no history of the disease, indicated that this mutation caused hypokalaemic periodic paralysis
type I in his family. Follow-up 2 years after adrenalectomy showed that the serum potassium concentration was
increased between paralyses and the number and severity of paralytic attacks were significantly decreased.
Conclusion: We identified a novel dominant mutation, c.1582C > T (p.Arg528Cys), in CACNA1S that causes hypokalaemic
periodic paralysis. The therapeutic effect of adrenalectomy indicated that unilateral adrenal hyperplasia might
make paralytic attacks more serious and more frequent by decreasing serum potassium. This finding suggests that
the surgical removal of hyperplastic tissues might relieve the symptoms of patients with severe hypokalaemic
paralysis caused by other incurable diseases, even if the adrenal lesion does not cause primary aldosteronism.
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Adrenal hyperplasia (AH) is a common endocrine disease,
and unilateral adrenal hyperplasia (UAH) is a common
cause of primary aldosteronism (PA) [1,2]. Muscular par-
alysis and decreased serum potassium are two of the initial
symptoms in some patients with PA-causing UAH, which
can be corrected by adrenalectomy [3,4]. However, it is
unclear whether adrenalectomy in patients with non-
PA-causing UAH increases serum potassium, which would
indicate that this surgery could relieve symptoms caused
by hypokalaemia resulting from other incurable diseases.
Hypokalaemic periodic paralysis (HOKPP), including
HOKPP1 (OMIM #170400) and HOKPP2 (OMIM
#613345), is a rare autosomal dominant inherited disease
characterised by episodic muscle weakness with significant
hypokalaemia (< 0.9 to 3.0 mmol/L) during attacks [5,6].
HOKPP1 and HOKPP2 are caused by mutations in CAC-
NA1S (calcium channel, voltage-dependent, L type, alpha
1S subunit) (OMIM #114208) and SCN4A (sodium channel,
voltage-gated, type IV, alpha subunit) (OMIM #603967),
respectively [7,8]. The frequency of HOKPP attacks varies
from daily to yearly, and the attacks typically last from
3–4 hours up to a day or longer [9]. The frequency of
attacks varies significantly among members of families
with HOKPP, and the cause for this variation remains
unknown.
In this case, we report the clinical features, diagnosis,
and prognosis after adrenalectomy in a patient with non-
PA-causing UAH and HOKPP and discuss the potential
of this surgery to relieve the symptoms of hypokalaemic
periodic paralysis.
Case presentation
A 43-year-old male presented to the outpatient Department
of Urology of West China Hospital in March 2012 with
severe paralytic attacks characterised by palpitations and
muscle weakness starting in the right thigh and spreading
to all limbs. A significant reduction in the serum
potassium concentration (1.89 mmol/L, reference value
3.5–5.0 mmol/L) was found during laboratory examin-
ation, and an ECG indicated severe potassium deficiency.
Symptoms remitted after taking oral potassium (50 ml of
10% potassium chloride was administered immediately
followed by an additional 50 ml over 24 h for a total dose
of 10 g). After the paralytic attack, a CT scan of the abdo-
men was performed, which revealed left UAH characterised
by a nodular mass on the left adrenal gland. Laboratory
examination showed a slight elevation in norepinephrine
(602 ng/L, reference value, 272–559 ng/L) and a reduction
in adrenaline (< 25 ng/L, reference value 54–122 ng/L)
in the serum. Other data, including the serum concentrations
of potassium (3.71 mmol/L), aldosterone (11.41 ng/dL, refer-
ence value 9.8–27.5 ng/dl), cortisol (7.3 μg/dL, reference
value 7.2–18.2 μg/dL), renin (2.22 ng/mL, reference value0.56–2.79 ng/ml), calcium (2.27 mmol/L, reference value
2.1–2.7 mmol/L), creatine kinase (58 IU/L, reference value
19–226 IU/L), lactate dehydrogenase (167 IU/L, reference
value 110–220 IU/L), alanine aminotransferase (19 IU/L,
reference value <55 IU/L), aspartate transaminase (15 IU/L,
reference value <46 IU/L), creatinine (74.5 μmol/L, reference
value 53–140 μmol/L), blood urea nitrogen (7.69 mmol/L,
reference value 3.30–8.22 mmol/L), thyroid-stimulating
hormone (6.3 mU/L, reference value 2–10 mU/L),
total-triiodothyronine (2.14 nmol/L, reference value
1.8–2.9 nmol/L), and total thyroxine (87 nmol/L, refer-
ence value 65156 nmol/L), were normal. The patient
did not have hypertension (117/83 mm Hg).
Patient history showed that the paralytic attacks were
usually triggered by physical labour or stress and were
periodic. Attack frequency varied from weekly during the
summer to bimonthly in the winter; each attack lasted
4–6 hours. This attack was the most severe of the
attacks he had experienced during the past decade. Al-
though these paralytic attacks were associated with
hypokalaemia, the aetiology had not been previously
established, and the patient had not received any
treatment, including potassium supplement, between
attacks. Two years before this attack, serum potassium
had been measured several times between attacks; the
results of three of these tests were available and were
3.74, 3.69 and 3.63 mmol/L.
Because of the presence of severe hypokalaemic periodic
paralysis, the patient underwent a left adrenalectomy after
admission. Examination of the adrenal gland revealed a
1.1-cm benign nodule at the periphery of the gland with
multiple cortical nodular hyperplasias. The patient did not
have any complications during the perioperative period
and laboratory results were normal (serum potassium
.87 mmol/L, serum sodium 143.9 mmol/L, norepinephrine
452 ng/L, adrenaline 60 ng/L, aldosterone 12.24 ng/dL,
cortisol 8.1 μg/dL, renin 2.13 ng/mL, creatine kinase
60 IU/L, lactate dehydrogenase 168 IU/L, alanine ami-
notransferase 20 IU/L, aspartate transaminase 16 IU/L,
creatinine 81.3 μmol/L, blood urea nitrogen 8.01 mmol/L).
He was discharged 4 days after surgery. During the next
3 months, while recovering at home, no paralytic attacks
occurred. The patient then returned to work, and the
acute paralytic crises soon recurred. A colour Doppler
ultrasound examination did not show any abnormality
of the right adrenal gland. The patient then asked for
help from the Department of Medical Genetics. His
serum potassium was monitored three times with a
frequency of once per month with results of 4.12, 3.97,
and 4.27 mmol/L, respectively. As shown in Figure 1, in
addition to the patient (II2), four other adult male family
members, including two uncles (I5 and I6), one brother
(II3), and one nephew (III1), also had a history of para-
lytic attacks, although their attacks were milder and less
Figure 1 Mutation Detection of CACNA1S in the Family of Hypokalaemic Periodic Paralysis, Type I (HOKPP1). Panel A shows the family
pedigree with the patient as the proband (arrow). Panel B shows the DNA sequencing results of CACNA1S of the patient and a healthy control
and the position of the c.1582C > T heterozygous mutation (arrow). The mutation leads to an amino acid substitution of Arg for Cys at the 528th
codon of CACNA1S.
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examination to determine the presence or absence of
UAH.
Because of the positive family history of periodic paraly-
sis with potential autosomal dominant inheritance, the
diagnosis of HOKPP was considered, and genetic testing
of the CACNA1S and SCN4A genes was performed using
Sanger sequencing of all exons and their splice sites.
Consequently, the patient was identified as a heterozy-
gote carrying a novel missense mutation, c.1582C > T, in
CACNA1S (p.Arg528Cys) (Figure 1). In his family, the
mutation was also detected in three other adult males
with periodic paralysis (I6, II3, and III1) and in two
asymptomatic females (II1 and III2). This mutation was
absent in two male family members who did not have a
history of symptoms (III3 and III4). Furthermore, the
targeted Sanger sequencing did not detect the mutation
in 130 adult male controls.
During the following 2 years, the patient maintained
the same diet as before surgery. He did not receive any
potassium supplement treatment and suffered 12 paralytic
attacks. However, there were considerably fewer attacks
(monthly in the summer and no attacks in the winter),
and the attacks were shorter in duration (2–3 hours) than
the attacks before adrenalectomy.
Discussion
Periodic paralysis caused by hypokalaemia possesses sig-
nificant aetiological heterogeneity. A recent study [10]
concluded that 42.9% of patients had a secondary cause,
including renal tubular acidosis, Gitelman syndrome, thyro-
toxicosis, alcoholism, hypothyroidism, Liddle’s syndrome,
gastroenteritis, and primary hyperaldosteronism. In the
other cases of primary periodic paralysis, 48.2% were spor-
adic and 8.9% had a positive family history [10]. Some of
the cases with a positive family history might be attributedto mutations in a single gene, such as CACNA1S or
SCN4A.
CACNA1S and SCN4A encode the human skeletal
muscle α1-subunit of a dihydropyridine-sensitive calcium
channel and the α-subunit of a sodium channel, respect-
ively [7,8]. Previous studies have linked mutations in these
genes to HOKPP. The mutant CACNA1S and SCN4A
have a partial loss of function, leading to reduced calcium
or sodium current density, which is followed by mem-
brane depolarisation. Membrane depolarisation is coupled
with the inflow of potassium into skeletal muscle cells,
causing paroxysmal hypokalaemia and periodic paralysis
[11,12]. In the present case, genetic testing revealed a mis-
sense mutation in CACNA1S, resulting in p.Arg528Cys.
This mutation had not been reported previously. A
genotype-phenotype correlation was identified in the
patient’s family by the cosegregation of the mutation
with all of the affected adult male members and a
higher penetrance in males. In all of the seven HOKPP1–
causing mutations that have been reported, two different
mutations involve the 528th codon of CACNA1S, includ-
ing p.Arg528His and p.Arg528Gly [5,13]. The arginine
residue encoded by the wild-type 528th codon is highly
conserved among different species from C. elegans to
humans, and it is located in the critical voltage sensor re-
gion of the transmembrane segment of the calcium chan-
nel [13]. The above evidence combined with the absence
of the mutation in the matched male controls strongly
suggests that the Arg528Cys substitution is a novel dom-
inant HOKPP1-causing mutation accounting for the onset
of hypokalaemic periodic paralysis in this patient’s family.
The patient also had UAH identified by a CT scan and
pathological examination. UAH possesses a pathogenic
mechanism distinct from HOKPP; however, the clinical
manifestations of the two diseases are similar when
UAH causes PA followed by hypokalaemia and muscular
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type of PA [15], whereas recent studies suggest that the
contribution of UAH to PA might have been underesti-
mated because high-resolution multi-slice CT and other
new screening tests have shown more patients with PA to
have UAH [2]. This finding is encouraging because PA
caused by UAH has been confirmed to be surgically cor-
rectable by adrenalectomy with excellent long-term results
[3]. In the present case, the patient did not display PA, but
his clinical manifestation was the most severe of his family
members with periodic paralysis based on attack fre-
quency and duration. In addition, there was no remis-
sion although he was over 43 years old, which could not
be completely explained by HOKPP1 alone. After adre-
nalectomy, the symptoms of the patient were signifi-
cantly relieved, including increased serum potassium
concentrations (t test, α = 0.05: P = 0.009) between crises
and decreased paralytic attack frequency and duration.
This observation suggests a close association between
the decreased serum potassium caused by UAH and the
severity of HOKPP and supports the hypothesis that ad-
renalectomy may be an effective treatment for relieving
the symptoms of patients with both UAH and severe
hypokalaemic paralysis resulting from some incurable
genetic diseases such as HOKPP and Gitelman syn-
drome [10,16].
Conclusions
In this first reported case of unilateral adrenal hyperpla-
sia in concurrence with hypokalaemic periodic paralysis,
we identified a novel dominant mutation, p.Arg528Cys,
of CACNA1S causing HOPPK, which is the third
known pathogenic mutation involving the 528th code
of CACNA1S. These results emphasise the importance
of CACNA1S Arg528 in maintaining calcium channel
function. The prognosis after adrenalectomy suggests
that the presence of UAH might increase the severity of
hypokalaemic paralysis caused by other diseases. Op-
erative treatment may be a rational choice for relieving
the symptoms of hypokalaemic paralysis by increasing
serum potassium, even if the UAH does not cause pri-
mary aldosteronism or clinical hypokalaemia.
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